LXRX

In the past six months, Lexicon Pharmaceuticals reported a basic EPS loss of $0.04 in Q4 2025, exceeding analysts' estimates. In Q1 2026, the company reported break-even EPS, surpassing analysts' estimates, with revenues soaring to $21.1 million due to a milestone payment from Novo Nordisk. Lexicon announced a $100 million loan facility with Hercules Capital. Positive Phase 2b data for pilavapadin was announced, supporting its advancement to Phase 3. Lexicon received a $10 million milestone payment from Novo Nordisk for LX9851. The stock hit a new 52-week high of $2.00 in May 2026 and has increased by 73.9% since January 1, 2026.